Liberum
MENU

News

Liberum appointed Joint Corporate Broker to Harworth Group Plc

12 February 2019 | Corporate Broker

Cover -65049

We are pleased to announce that Liberum has been appointed as Joint Corporate Broker to Harworth Group Plc, alongside Peel Hunt.

Harworth Group plc (“Harworth” or the “Company”) is a leading regenerator of brownfield land. It owns, develops and manages a c.£530m portfolio of approximately 21,000 acres of land on sites located throughout the Midlands, Yorkshire and the North of England. The Company is focused on purchasing large, complex and often dirty redevelopment sites and using its in-house technical skills to obtain planning consent and then to remediate and engineer the land for its sale and/or development, predominantly for residential and commercial uses.

The Company was spun out of Coalfield Resources plc (formerly UK Coal) in 2015. Harworth transferred its standard listing to a premium listing in August 2018.

Liberum has been appointed as Joint Corporate Broker with immediate effect.

Liberum Team

Investment Banking – Jamie Richards, Jonathan Wilkes-Green, Laura Hamilton
Sales –
John Mozley
Research –
David Brockton, James Ashley
Corporate Access –
Lynsey Cox, Natalie Clarke 

Twitter@LiberumToday

LinkedInLiberum

 

Liberum acts as Joint Bookrunner in relation to a placing by SigmaRoc plc

31 January 2019 | Bookrunner

Sigma Roc

Liberum is pleased to announce that it acted as Joint Bookrunner in relation to a placing by SigmaRoc plc, raising £12.4 million. The placing part funded the acquisition of CCP Building Products Ltd for a total consideration of £15.2 million.

SigmaRoc is a buy-and-build construction materials company that aims to create value by purchasing assets in fragmented construction materials markets and extracting efficiencies through active management and forming the assets into larger groups.

CCP is one of the largest vertically integrated manufacturer and supplier of pre-cast concrete products and aggregates in the North West of England and North Wales. CCP comes with a very attractive asset footprint with high barriers to entry, including secured internal raw material supply.

CCP represents a strategic fit within SigmaRoc, putting the Company in a strong position in the UK market place going forward and allowing it to continue its growth story. The transaction will provide consistent organic EBITDA growth and cash flow generation, with the retained senior management team incentivised to achieve ambitious EBITDA milestones over the three years.

Liberum Team

Board – Shane Le Prevost

Research – Charlie Campbell, Marcus Cole

Sales – Oliver Baxendale, Alistair Smallwood

Investment Banking – Neil Patel, Jamie Richards, Jonathan Wilkes-Green, William Hall, Ant Schia

Corporate Access – Natalie Clarke

Twitter@LiberumToday

LinkedInLiberum

Liberum appointed as Joint Corporate Broker to XPS Pensions Group Plc

23 January 2019 | Joint Corporate Broker

XPS

Liberum is pleased to announce its appointment as Joint Corporate Broker to XPS Pensions Group Plc.

XPS is a pensions actuarial, consulting and administration business which provides a wide range of services to over 1,200 pension scheme clients and undertakes administration for over 585,000 scheme members.

In December 2017, Liberum acted as joint bookrunner and sole underwriter to the Company in connection with the acquisition of Punter Southall’s actuarial, administration and investment consulting businesses and the associated £70 million Capital Raising.

Liberum has been appointed as Joint Corporate Broker alongside RBC with immediate effect.

Investment Banking – Richard Crawley, Robert Morton, Cameron Duncan, Jonathan Wilkes-Green, Will Hall

Research – Rahim Karim

Sales – Julian Collett, Steve Keeling

Corporate AccessLynsey Cox

Twitter@LiberumToday

LinkedInLiberum

Liberum acts as Joint Bookrunner on a £68m ABB for Genus Plc

17 December 2018 | Bookrunner

Genus 

Liberum is pleased to announce that it acted as Joint Bookrunner in relation to a 5% placing of Genus Plc’s issued share capital, raising £68 million.

Genus, a FTSE 250 company, is a world-leading animal genetics company headquartered in the UK. The Company continuously develops higher quality pigs and cows for farmers, by selecting animals with desirable characteristics that help them to produce higher quality meat and milk more sustainably.

Net proceeds will be applied to reduce the Company’s net debt position (£108.5m at 30 June 2018), following a series of acquisitions and capex investments in recent years, and to provide balance sheet flexibility to continue to capture growth opportunities.

Management see continued opportunities to strengthen and grow the Genus business further through acquisition and business development transactions. Following the placing, the
net debt/EBITDA is expected to be in the
region of 1.0x. 

Liberum Team

Investment Banking – Clayton Bush, Josh Hughes, Trystan Cullen, Laura Hamilton
Sales –
David Parsons, Julian Collett
Research –
Sophie Jourdier
Corporate Access –
Lynsey Cox, Natalie Clarke 

Twitter@LiberumToday

LinkedInLiberum

Liberum acts as Nominated Adviser & Sole Bookrunner on the £29 million fundraise for Science in Sport plc

06 December 2018 |

SIS (1)

Liberum is pleased to announce that it acted as Financial Adviser, Nominated Adviser and Sole Bookrunner in relation to a placing & acquisition by Science in Sport plc, raising £29 million. The placing part funded the acquisition of PhD Nutrition Ltd for a total consideration of £32 million.

Science in Sport plc, a UK-headquartered market leading sports nutrition company that develops, manufactures and markets sports nutrition products for professional athletes and sports enthusiasts.

PhD is a UK-headquartered premium protein brand, which has developed into one of the UK's leading protein brands with a reputation for high quality and innovative products aimed at sports enthusiasts and gym lifestyle consumers.

The deal doubles the size of the Company and accelerates their ambition to become a global leader in premium performance nutrition. SIS and PhD are two businesses that have complementary brands, products, operations and sales channels which together create a well-balanced, cash generative company with enhanced potential.

Liberum Team 

Investment BankingClayton Bush, Chris Clarke, James Greenwood, William Hall, Stephanie Poulier

Sales – Oliver Baxendale, Julian Collett, Gerard O’Doherty, Sebastian Fernandez

Research – Wayne Brown, Tom Musson

Corporate Access – Marcio Remedios

Twitter@LiberumToday

LinkedInLiberum

 

Liberum appointed Joint Corporate Broker to TruFin

29 November 2018 | Corporate Broker

Tru Fin

Liberum is pleased to announce its appointment as Joint Corporate Broker to TruFin plc  (“TruFin”).

TruFin is the holding company of an operatinggroup comprising three growth-focused FinTech and banking businesses operating in three niche lending markets: DF Capital (supply chain finance), Satago (invoice finance) and Oxygen Finance (dynamic discounting).

In addition, TruFin owns a c.13% minority stake in Zopa, a leading UK consumer P2P lender, which operates independently of TruFin.

TruFin was established through a series of acquisitions and investments by Arrowgrass between 2014 and 2017 and completed an AIM IPO in February 2018. It currently has 100 employees with offices in the UK and a small team in the US.

Liberum has been appointed as Joint Corporate Broker with immediate effect. Macquarie acts as TruFin’s Nominated Adviser and Joint Corporate Broker.

Liberum Team

Investment Banking - Chris Clarke, Trystan Cullen, Louis Davies, Stephanie Poulier

Sales -  Julian Collett, Steve Keeling

Research - Ben Williams, Jamie Donald

Corporate Access - Lynsey Cox

Follow Liberum

Twitter@LiberumToday

LinkedInLiberum